Journal Pre-proof J o u r n a l P r e -p r o o f 2 ABSTRACT Energy supply to the brain is essential to ensure correct neuronal function, and glucose is the main fuel utilized by neurons. In metabolically challenging situations when glucose availability is restricted, brain cells may switch to alternative carbon substrates. This ensures energy supply to preserve the functions of the central nervous system. In this regard, ketone bodies, a by-product of fat metabolism, play a key role.
INTRODUCTION
The brain needs large amounts of energy to carry out its functions. To meet its high energy requirements, it takes up to 25% of the glucose supply to the whole body, and about 20% of available oxygen is dedicated to support brain function (Belanger et al., 2011) . Glucose is the main fuel of the brain, although brain cells can oxidize alternative substrates as "energy fuels", such as lactate, glutamine or ketone bodies, including -hydroxybutyrate (HB) or acetoacetate (Zielke et al., 2009) . In fact, the ability of brain cells to switch their preference from glucose to alternative carbon substrates can have profound effects on neuronal function and survival (Katsu-Jimenez et al., 2017) . However, to date very little is known about the molecular mechanisms that govern the metabolic adaptation of brain cells to use different energy fuels. This is particularly relevant in situations of prolonged fasting, when neurons are forced to switch from glucose to ketone bodies to prevent energy deficiency and subsequent cell damage. Ketone bodies derive from fatty acid breakdown and are mainly synthesized in the liver during situations such as fasting, extenuating exercise, or pathological conditions in which glucose uptake, sensing and/or utilization are compromised, including diabetes. Importantly, they can provide up to 60% of the J o u r n a l P r e -p r o o f 5 fasting or using diets that favor ketogenesis has a major impact to treat pharmacoresistant epilepsy (Lutas and Yellen, 2013) .
Compelling evidence has shown that certain neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) impact neuronal energy metabolism (Burkhalter et al., 2003) . Moreover, previous studies have shown that phosphoregulatory mechanisms can influence the preference for select carbon substrates, as illustrated by the metabolic switch imparted by the BCL-2 protein BAD upon phosphorylation, which shifts the preference of neurons and glial cells from glucose to the ketone body HB (Gimenez-Cassina et al., 2012b) . Taken together, these works support the notion that neuronal metabolic flow and preferences are tightly regulated by signaling pathways that can be modulated by extracellular cues.
Fibroblast Growth Factor-21 (FGF21) is a peptide hormone secreted by several organs with significant impact in whole-body energy homeostasis, increasing energy expenditure (Fisher and Maratos-Flier, 2016) . FGF21 is secreted during fasting, and contributes to adapt several tissues to ketosis, such as liver and adipose tissue (Domouzoglou and Maratos-Flier, 2011) . This is underscored by the fact that genetic J o u r n a l P r e -p r o o f 6 2014). In this regard, some studies have shown that FGF21 can cross the blood-brain barrier (Sa-Nguanmoo et al., 2016) , supporting the notion that FGF21 may play a role in neurons in charge of cognitive functions independent from its role in systemic metabolism.
In this work, we have examined the role of FGF21 in modulating metabolic signaling and substrate utilization in cortical neurons in fasting-like conditions, with special emphasis on ketone bodies. We show that FGF21 favors the ability of neurons to utilize ketone bodies to generate ATP. Furthermore, we determine that this is at least partly mediated by AMP-dependent kinase (AMPK) signaling. Altogether, our results suggest that FGF21 may participate in modulating brain metabolism during fasting by priming neurons to use obtain ATP from ketone bodies more efficiently. We propose that FGF21 may contribute to prepare neurons for situations of reduced glucose availability.
MATERIALS AND METHODS

Reagents
N2 supplement, L-Glutamine, Sodium Pyruvate were from Thermo Fisher Scientific (Waltham, MA, USA); Compound C was from Merck KGaA (Darmstadt, Germany); J o u r n a l P r e -p r o o f 8 Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 15% Fetal Bovine Serum (FBS, Sigma-Aldrich, St.Louis, MO, US), 2 mM GlutaMaxI (both Thermo Fisher Scientific, Waltham, MA, USA), and a mix of penicillin and streptomycin (100 U/ml and 100 μg/ml, respectively). After 24 hours the medium was changed to 10% Fetal Bovine Serum (FBS, Sigma-Aldrich, St.Louis, MO, US), 2mM GlutaMaxI (both Thermo Fisher Scientific, Waltham, MA, USA), and a mix of penicillin and streptomycin (100 U/ml and 100 μg/ml, respectively). Every 48 hours the medium was changed until reaching 100% confluency.
Lentiviral vector packaging
Lentiviral vectors encoding short-hairpin RNA sequences against AMPK1 (Prkaa1; NM_001013367) or AMPK2 (Prkaa2; NM_178143) were purchased from Sigma-Aldrich. An additional vector containing a short-hairpin scrambled sequence with no known murine target used as a control vector was also purchased from Sigma-Aldrich. Lentiviral packaging and titration were performed as described previously (Follenzi and Naldini, 2002) .
Animals
8-week-old male C57BL/6 mice (Janvier Labs, Le Genest-Saint-Isle, France) were used in this study and the mice were housed in a temperature-controlled room under a 12-hour light/12-hour dark cycle, with free access to food and water ad libitum. When animals were subjected to fasting, a group of 4 animals was transferred J o u r n a l P r e -p r o o f 9 approval from the regional animal ethics committee of Northern Stockholm, Sweden (protocol number N213/15), according to institutional and European guidelines for animal handling and research (EU Directive 2010/63/EU for animal experiments). All efforts were made to minimize the number and suffering of used animals.
ATP quantification
ATP was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA). Briefly, cells were cultured in 96-well plates with opaque walls and clear bottom. At the end of each treatment 100 μl of CellTiter-Glo reagent was added to lyse the cells. After a 10-min incubation at room temperature, luminescence was recorded in a luminometer Infinite M200 Pro (Tecan Zürich, Switzerland). Five replicates were analyzed in at least three independent experiments for each experimental condition.
Western blot analysis
For protein extracts, cells were washed once with phosphate-buffered saline (PBS), placed on ice, and then homogenized in a buffer containing: 20 mM HEPES, pH 7.4; 100 mM sodium chloride (NaCl); 100 mM sodium fluoride (NaF); 1% Triton X-100; 1 mM sodium orthovanadate (Na 3 VO 4 ); 5 mM EDTA; the Complete TM protease inhibitor cocktail and PhosStop phosphatase inhibitors (both from Roche The membranes were then rinsed at least three times in PBST and incubated with the corresponding peroxidase-conjugated secondary antibody (Southern Biotech, Birmingham, AL, USA) for 1 hour at room temperature. The immunoreactive proteins were visualized by using an enhanced chemiluminescence detection system (Amersham GE Healthcare, Buckinghamshire, UK), and subsequent densitometric analysis was performed with a ChemIDoc XRS scanner and the ImageJ Software 
Reverse transcription and quantitative PCR (qPCR)
Total RNA (1μg in 20 μL) was reverse transcribed into cDNA ( Primers (mouse) were designed from previously published sequences or in house (Table 1) 
Enzyme-linked immunosorbent assay (ELISA)
FGF21 levels in cortical tissue were determined using a Sandwich-ELISA kit (cat.
#RD291108200R) from BioVendor LM (Karasek, Brno, Czech Republic). Mouse cortices were mechanically homogenized in lysis buffer (as described above for western blot), and 100-150 g were used in the aforementioned ELISA kit to determine FGF21 levels, following the manufacturer's instructions. The results were then normalized by the total amount of protein in each sample. Each sample was measured in duplicate.
Mitochondrial respiration
Oxygen consumption rate (OCR) in real time on primary neurons was determined using a Seahorse XF24 Extracellular Flux Analyzer (Agilent, Santa Clara, CA, US) as previously described (Ribeiro et al., 2015) . In brief, primary neurons were seeded onto poly-L-lysine-precoated XF24 microplates at a density of 1.5x10 5 cells per well. After 5 days in vitro, cells were changed to DMEM supplemented with 2 mM pyruvate, and then they were treated with different compounds as indicated in the "Results" section to manipulate pyruvate or -HB entry into mitochondria, followed by treatment with the ionophore FCCP (0.75 M)
to dissipate the proton gradient across the mitochondrial inner membrane and force maximal respiration, and the mitochondrial complex III inhibitor antimycin (4 M).
In every experiment, each condition was replicated in 4-6 wells per experiment, in at 
Statistical analysis
Results are expressed as mean ± SEM values, and at least three independent experiments from independent culture sessions are represented in the figures.
Statistical comparison of the data sets was performed using Student´s t-test between two groups, or ANOVA when there were more than two groups in the analysis. The differences are presented with their corresponding statistical significances or P-value, which is the probability that the observation in a sample occurred merely by chance under the null hypothesis. Statistical significance was attributed when P≤0.05.
RESULTS
Characterization of ATP levels and signaling profile during starvation in brain cells
To understand better how the switch between different carbon substrates is regulated in the brain, we first set out to characterize the metabolic and signaling profile of neurons in response to nutrient deprivation. This would allow us to understand how neurons react to complete lack of energy fuel, and their ability to utilize alternative carbon substrates. To this end, we first subjected primary rodent cortical neurons to complete starvation for different periods of time up to 6 hours by switching them to DMEM without glucose, glutamine or pyruvate (Fig. 1A) . We observed that after 30 minutes of nutrient deprivation, the ATP levels significantly plummeted, and after 1 hour they were below 10% of the original levels. In contrast, J o u r n a l P r e -p r o o f 14 primary cortical astrocytes were able to maintain their ATP levels above 50% in the medium depleted of glucose, glutamine and pyruvate (Fig. 1 B) . These results are consistent with the notion that astrocytes can store energy in form of glycogen (Wiesinger et al., 1997) , and underscore that neurons rely heavily on external supply of energy fuels to maintain their ATP levels. Of note, the ATP levels were not dependent on trophic factor support, as the addition of the N2 supplement (with insulin, transferrin, progesterone, putrescine and selenite), a basic formulation often used to maintain primary neurons in culture (Bunt-Milam, 1983 ), did not have any effect on the ATP levels ( Fig. 1A-B ). The rationale behind using N2 rather than B27
(the standard growth factor cocktail for culturing primary cortical neurons) is that B27
contains galactose, which can be used by neurons as a carbon substrate, thus affecting the analysis of results. By replacing B27 with N2, we preserve survival signals while eliminating undesired metabolic substrates.
We next characterized the signaling profile of neurons upon starvation. We first focused on the AMP-dependent kinase (AMPK) and mechanistic target of rapamycin (mTOR) pathways. The AMPK and mTOR signaling pathways are the J o u r n a l P r e -p r o o f 4B). However, exposure to FGF21 significantly expedited this process, preventing ATP levels from dropping too low.
To confirm these results, we used a different approach to monitor the effects of FGF21 on -HB utilization. Given that the utilization of pyruvate and ketone bodies require oxidative phosphorylation at mitochondria, we designed an experiment aimed at studying the ability of neuronal mitochondria to switch from pyruvate to the ketone body -HB. To this end, we used extracellular flux analysis, which allows us to determine mitochondrial oxygen consumption in real time (Wu et al., 2007) . With this analysis, we can determine the neuronal mitochondrial respiratory capacity in the presence of a given carbon substrate, which reflects the ability of neurons to use the carbon substrate of study as source of energy (Gimenez-Cassina et al., 2012b). As depicted in Figure 4C , we started by incubating primary cortical neurons with DMEM supplemented with 2 mM pyruvate. The extracellular flux analysis instrument does not allow to wash out any compounds, but rather works through sequential injection of compounds that are added on top of each other. Therefore, to switch carbon substrates, we injected UK5099 (1.5 M), a potent blocker of the mitochondrial pyruvate carrier that works well in cortical neurons (Halestrap, 1975; Jourdain et al., J o u r n a l P r e -p r o o f al., 2012b) (Fig. 4D ). The increase in maximal respiratory capacity is the highest when cells were kept in pyruvate, while preventing the use of pyruvate by adding UK-5099 led to a significant inhibition of respiration (Fig. 4D) . Supplying the cells with -HB could attenuate the drop in respiration after addition of UK-5099, but treatment with FGF21 significantly improved the respiratory rate of cells in the presence of -HB ( Fig. 4D) , while the addition of FGF21 alone, without -HB, had no effect on respiration (Suppl. Fig. 1) .
Altogether, and using two different approaches, our results indicate that FGF21 contributes to increase the preference of neurons to oxidize the ketone body -HB to generate ATP
FGF21 promotes ketone body utilization through activation of AMP-dependent kinase
Since we had previously seen that FGF21 can activate AMPK in neurons, we asked whether AMPK could mediate the effect of FGF21 on ketone body utilization ( Fig. 5A ). To this end, we treated cells with FGF21 and the AMPK inhibitor Compound C (Zhou et al., 2001) for 1 hour in the presence of -HB, and we saw that Compound C was able to modestly but significantly reduce the ability of FGF21 to promote ketone body utilization as determined by ATP production. Importantly, Compound C had no effect on pyruvate utilization. We also examined the contribution of the ERK pathway to FGF21 effect on -HB utilization, in case it could have any involvement, even if FGF21 did not elicit a consistent ERK response in Journal Pre-proof J o u r n a l P r e -p r o o f 19 neurons. Interestingly, we observed that inhibition of ERK with U0126 impaired FGF21-mediated increase in -HB utilization. However, the effect of U0126 extended also to pyruvate utilization, suggesting that rather than impairing specifically FGF21 effects, U0126 interfered unspecifically with oxidative metabolism. Of note, we confirmed by western blot that Compound C and U0126 inhibited AMPK and ERK, respectively.
We also approached this question by determining mitochondrial respiration in real time using extracellular flux analysis ( Fig. 5C-D) . Similar to our previous experiment, and when oxidation of pyruvate is prevented by UK-5099, FGF21 significantly increased neuronal maximal respiratory capacity in the presence of -HB ( Fig. 5D ). Consistent with our results measuring ATP levels, the effect of FGF21 on -HB-induced respiration was significantly abolished in the presence of Compound C, thus supporting the notion that the effects of FGF21 are at least in part mediated by AMPK.
To further confirm the involvement of AMPK in mediating FGF21 effects on ketone body metabolism, we used a genetic approach by silencing selectively the expression of AMPK, the catalytic subunit of AMPK. Given that there are two AMPK isoforms, AMPK1 and AMPK2, we used two different lentiviral vectors encoding short-hairpin RNA (shRNA) to silence the expression of AMPK1 and AMPK2, respectively; and a lentiviral vector encoding a shRNA scrambled sequence with no known target in the murine genome was used as control (Suppl. Fig.   2) . Surprisingly, AMPK1 silencing had no effect on FGF21-enhanced ketone body utilization (Fig. 6 ). However, AMPK2 silencing had a dramatic effect on ketone body utilization (Fig. 6) , similar to that observed with the AMPK inhibitor Compound Journal Pre-proof J o u r n a l P r e -p r o o f 20 C (Fig. 5) . Altogether, our results suggest that AMPK2 is the catalytic AMPK isoform that mediates the effects of FGF21 on ketone body metabolism in neurons.
Finally, to rule out any additional signaling mechanisms triggered by extracellular -HB through its receptor GPR109a (Katsu-Jimenez et al., 2017) , we also used the GPR109a antagonist mepenzolate bromide (Salem and Wadie, 2017) , which seemed to activate AMPK (Fig. 5B) , but had no effects on ATP levels (data not shown). Of note, GPR109a expression was detectable in cortical neurons, and its expression was actually increased in response to -HB (data not shown).
Overnight fasting does not induce FGF21 mRNA expression in the mouse cortex
Last, we set out to determine whether FGF21 that acts in the brain arises from peripheral organs or if it can be synthesized locally in the central nervous system. The expression and subsequent secretion of FGF21 in the liver significantly increases upon fasting (Estall et al., 2009; Fisher and Maratos-Flier, 2016) , and previous studies have shown that FGF21 can cross the blood-brain barrier (Hsuchou et al., 2007; Sa-Nguanmoo et al., 2016) . Other studies also have reported that cultured cortical astrocytes express FGF21 (Makela et al., 2014) . In order to determine in vivo if FGF21 can be synthesized in the brain, we subjected mice to an overnight fasting for J o u r n a l P r e -p r o o f 24 that neuronal endoplasmic reticulum stress, as well as other models of pathological stress in neurodegeneration can increase FGF21 expression in the brain, thus supporting local production of FGF21 in the brain (Restelli et al., 2018) , in addition to any FGF21 secreted from peripheral organs that may impact neural cells.
If glial cells express and secrete FGF21, what are the signals that induce its expression, beyond neurodegenerative insults? We could not find upregulation of Fgf21 mRNA in the rodent brain after 16 hours of fasting, while its expression was already significantly upregulated in the liver, consistent with previous studies (Estall et al., 2009 ). However, after 16 hours of fasting, gluconeogenesis in the liver is significantly activated to maintain normoglycaemia (Sharabi et al., 2015) , which could delay the induction of Fgf21 in the brain. Therefore, we cannot rule out that longer fasting periods may be able to induce astrocytic expression of Fgf21.
Alternately, the induction of Fgf21 expression in glial cells may require other signals that need to be identified.
In any case, cortical neurons respond to FGF21 by activating AMPK signaling, which is consistent with AMPK activation by FGF21 in other tissues (Fisher and Maratos-Flier, 2016) . In fact, albeit it is not completely clear how FGF21 activates AMPK, it is thought that FGFR signaling can impinge on LKB1, an upstream activator of AMPK, which subsequently could activate AMPK (reviewed in Salminen et al., 2017) .
J o u r n a l P r e -p r o o f activation, as seen in Figure 5 . This reduction of ERK inhibition on pyruvate-and -HB-driven ATP levels could lead to an energy crisis that subsequently activates AMPK. The possibility that ERK may play a central role in modulating energy metabolism in neurons, and the crosstalk between the AMPK and the ERK pathways, deserve further investigation.
Another important question concerns the molecular mechanism through which FGF21 increases the ability of neurons to use ketone bodies. FGF21 favors ketone body utilization in neurons as early as 30 minutes after switching from glucose/pyruvate to -HB. Such short timing points to post-translational modifications rather than transcriptional adaptation, at least for the early stages of FGF21-mediated adaptation to ketone body utilization. A post-translational modification-related mechanism is supported by the immediate effect of AMPK inhibition on ketone body utilization.
The identification of the precise substrate(s) downstream AMPK signaling that modulates the preference for -HB in neurons will provide useful information to understand how metabolic plasticity and adaptation to nutritional states are regulated in the brain.
In summary, in this work we show that FGF21 plays a role in modulating ketone body metabolism in cortical neurons in an AMPK-dependent manner. It had been previously shown that FGF21 contributes to the transition from the fed to the fasted state by adapting the metabolic program to the fasted state in peripheral tissues. Here we propose that FGF21 also may contribute to prepare the brain to situations of 
